Home/Pipeline/ZP8396

ZP8396

Obesity

Preclinical/Phase 1Active

Key Facts

Indication

Obesity

Phase

Preclinical/Phase 1

Status

Active

Company

Zealand Pharma

About Zealand Pharma

Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.

View full company profile

Therapeutic Areas

Metabolic Diseases Gastrointestinal Diseases Endocrinology

Other Obesity Drugs

Drug	Company	Phase	Status
Tirzepatide (Zepbound)	Eli Lilly	Approved	Commercial
APJ Program	BioAge Labs	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (subcutaneous)	Viking Therapeutics	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active
PL7737	Palatin Technologies	Preclinical	Active